A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (A...

書誌詳細
主要な著者:	Naoto Saito, Takeshi Hatanaka, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga, Kenji Kashiwabara, Norio Kubo, Yasuo Hosouchi, Hiroki Tojima, Satoru Kakizaki, Toshio Uraoka
フォーマット:	論文
言語:	English
出版事項:	Wiley 2022-07-01
シリーズ:	Clinical Case Reports
主題:	anti‐programmed death ligand‐1 hepatic resection immune checkpoint inhibitor liver cancer vascular endothelial growth factor
オンライン･アクセス:	https://doi.org/10.1002/ccr3.6129

類似資料

Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
著者:: Takeshi Hatanaka, 等
出版事項: (2024-03-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
著者:: Tomoyuki Satake, 等
出版事項: (2023-07-01)

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
著者:: Alessandro Rizzo, 等
出版事項: (2021-12-01)

Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients– multicenter analysis
著者:: Atsushi Hiraoka, 等
出版事項: (2022-12-01)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysisResearch in context
著者:: Anand V. Kulkarni, 等
出版事項: (2023-09-01)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
著者:: Toshifumi Tada, 等
出版事項: (2023-04-01)

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
著者:: Supachaya Sriphoosanaphan, 等
出版事項: (2024-01-01)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
著者:: Atsushi Hiraoka, 等
出版事項: (2023-01-01)

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
著者:: Takahiro Kinami, 等
出版事項: (2024-03-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
著者:: Ryosuke Tsunemitsu, 等
出版事項: (2023-06-01)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
著者:: Loïg Gaugain, 等
出版事項: (2023-01-01)

Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
著者:: Shinpei Yamaba, 等
出版事項: (2024-01-01)

Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
著者:: Yusuke Johira, 等
出版事項: (2021-11-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
著者:: Yasuhito Mitsuyama, MD, 等
出版事項: (2023-09-01)

Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
著者:: Shunichi Hosoda, 等
出版事項: (2022-10-01)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
著者:: Rene John D. Febro, 等
出版事項: (2024-09-01)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
著者:: Hannah Yang, 等
出版事項: (2023-04-01)

Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
著者:: Yuwa Ando, 等
出版事項: (2022-11-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
著者:: Tetsu Tomonari, 等
出版事項: (2023-02-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
著者:: Zili Hu, 等
出版事項: (2024-11-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
著者:: Shen X, 等
出版事項: (2024-10-01)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
著者:: Toshifumi Tada, 等
出版事項: (2023-03-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
著者:: Jie Dai, 等
出版事項: (2025-01-01)

P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
著者:: Cristina Cheinquer Coelho Borges, 等
出版事項: (2024-12-01)

A case of biopsy‐proven acute interstitial nephritis following atezolizumab‐bevacizumab treatment of advanced unresectable hepatocellular carcinoma
著者:: Reema Patel, 等
出版事項: (2024-07-01)

Case report: The efficacy of adding high doses of intravenous vitamin C to the combination therapy of atezolizumab and bevacizumab in unresectable HCC
著者:: Waleed Kian, 等
出版事項: (2024-10-01)

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma
著者:: Alexander Villalobos, 等
出版事項: (2023-11-01)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
著者:: Chung‐Wei Su, 等
出版事項: (2023-03-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
著者:: Zhao C, 等
出版事項: (2023-07-01)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
著者:: Kei Endo, 等
出版事項: (2022-08-01)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
著者:: Awiwi MO, 等
出版事項: (2022-08-01)

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
著者:: Colby S. Shemesh, 等
出版事項: (2021-06-01)

Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
著者:: Tasuku Nakabori, 等
出版事項: (2024-03-01)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
著者:: Chien-Yu Tseng, 等
出版事項: (2023-11-01)

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
著者:: Chanchai Charonpongsuntorn, 等
出版事項: (2022-12-01)

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
著者:: Masatoshi Kudo
出版事項: (2022-07-01)

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
著者:: Arndt Vogel, 等
出版事項: (2021-05-01)

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
著者:: Yulei Wang, 等
出版事項: (2021-08-01)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
著者:: Takahiro Niimura, 等
出版事項: (2023-08-01)

Downstaging with atezolizumab-bevacizumab: a case series
著者:: Anand V. Kulkarni, 等
出版事項: (2024-09-01)